FKBP4 and melanoma: Because doxorubicin-induced NF-κB activation is counteracted by FKBP51 inhibition [8, 13], we performed an electrophoretic mobility shift assay (EMSA) of nuclear extracts from melanoma cells to investigate the SAFit effect on NF-κB.